New Study Results Immiment for Implantable Heartpump
Published date : 21 August 2013
Article date : 20 August 2013
Mass Device reports that medical device manufacturer HeartWare is progressing a premarket approval application with the FDA. The company anticipates that new study results will address concerns about the rate of neurological events associated with with its Endurance implantable heart pump.
They say that researchers noted an unexpectedly high rate of ischemic and hemorrhagic strokes in HeartWare patients (6.7% and 5.1% respectively) in comparison to a control pump (4.3% and 0%, respectively). Apparently, Heartware subsequently targeted blood pressure management as a potential route for stemming further adverse events.
The manufacturer is working towards presenting the latest clinical findings at the 2014 American Heart Association or the subsequent meeting of the American College of Cardiology.
Source: Mass Device
